Ran Reshef, MD, director of translational research, Blood and Marrow Transplantation Program, Columbia University, clinical lead, CAR-T Cell Program, principal investigator, Columbia Center for Translational Immunology, member, Herbert Irving Comprehensive Cancer Center, discusses findings from the phase 3 BMT CTN 1703 trial (NCT03959241) examining graft-vs-host disease (GVHD) prophylaxis in reduced intensity conditioning.

The study compared outcomes of those randomized to receive a prophylactic regimen comprised of cyclophosphamide, tacrolimus, and mycophenolate mofetil (CellCept) vs the standard strategy of tacrolimus plus methotrexate in patients with hematologic malignancies following allogeneic hematopoietic cell transplantation.

Data presented at the 2022 ASH Annual Meeting showed that those who received the triplet had a significantly lower hazard of GVHD/relapse or progression-free survival (GRFS) vs those who received the doublet, with 1-year GRFS rates of 52.7% and 34.9%, respectively, Reshef says.

These data demonstrated a clinically meaningful difference in GRFS between the 2 regimens, and findings from this trial have the potential to be practice changing, Reshef concludes.

Videos

Ran Reshef, MD, discusses findings from the phase 3 BMT CTN 1703 trial examining graft-vs-host disease prophylaxis in reduced intensity conditioning.

Ran Reshef, MD

Articles

Dr Reshef on Data From the BMT CTN 1703 Trial Evaluating Post-Transplant GVHD Prophylactic Regimens